Review

rabbit polyclonal antibody against muc5b (Novus Biologicals)

Novus Biologicals is a verified supplier

Novus Biologicals manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Novus Biologicals rabbit polyclonal antibody against muc5b

Figure 3. Localization and quantification of <t>MUC5B</t> and MUC5AC in the human uterus during pregnancy and after trachelectomy. (A) Schema of uterine section. (B-G) Representative MUC5B and MUC5AC expression in the human uterus. Right panels are magnified images. A nonpregnant woman (B and E), a pregnant woman at 35 weeks of gestation (C and F), and a nonpregnant woman after trachelectomy (D and G). (H) The areas of cervical glands in 6 normal pregnant women compared with those in 9 nonpregnant women. (I and J) Quantification of MUC5B- and MUC5AC-positive areas in 6 normal pregnant women and 4 nonpregnant women after trachelectomy compared with those in 9 nonpregnant women. Data are represented as the median ± interquartile range. **P < .01, ***P < .001 using a 2-tailed Mann–Whitney U test. Cx, cervix; Ub, uterine body; Va, vagina; Scale bars, 1 mm.

Rabbit Polyclonal Antibody Against Muc5b, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit polyclonal antibody against muc5b/product/Novus Biologicals
Average 94 stars, based on 10 article reviews

rabbit polyclonal antibody against muc5b - by Bioz Stars, 2026-05

94/100 stars

Images

1) Product Images from "Cervical MUC5B and MUC5AC are Barriers to Ascending Pathogens During Pregnancy."

Article Title: Cervical MUC5B and MUC5AC are Barriers to Ascending Pathogens During Pregnancy.

Journal: The Journal of clinical endocrinology and metabolism

doi: 10.1210/clinem/dgac545

Figure 3. Localization and quantification of MUC5B and MUC5AC in the human uterus during pregnancy and after trachelectomy. (A) Schema of uterine section. (B-G) Representative MUC5B and MUC5AC expression in the human uterus. Right panels are magnified images. A nonpregnant woman (B and E), a pregnant woman at 35 weeks of gestation (C and F), and a nonpregnant woman after trachelectomy (D and G). (H) The areas of cervical glands in 6 normal pregnant women compared with those in 9 nonpregnant women. (I and J) Quantification of MUC5B- and MUC5AC-positive areas in 6 normal pregnant women and 4 nonpregnant women after trachelectomy compared with those in 9 nonpregnant women. Data are represented as the median ± interquartile range. **P < .01, ***P < .001 using a 2-tailed Mann–Whitney U test. Cx, cervix; Ub, uterine body; Va, vagina; Scale bars, 1 mm.

Figure Legend Snippet: Figure 3. Localization and quantification of MUC5B and MUC5AC in the human uterus during pregnancy and after trachelectomy. (A) Schema of uterine section. (B-G) Representative MUC5B and MUC5AC expression in the human uterus. Right panels are magnified images. A nonpregnant woman (B and E), a pregnant woman at 35 weeks of gestation (C and F), and a nonpregnant woman after trachelectomy (D and G). (H) The areas of cervical glands in 6 normal pregnant women compared with those in 9 nonpregnant women. (I and J) Quantification of MUC5B- and MUC5AC-positive areas in 6 normal pregnant women and 4 nonpregnant women after trachelectomy compared with those in 9 nonpregnant women. Data are represented as the median ± interquartile range. **P < .01, ***P < .001 using a 2-tailed Mann–Whitney U test. Cx, cervix; Ub, uterine body; Va, vagina; Scale bars, 1 mm.

Techniques Used: Expressing, MANN-WHITNEY

Figure 4. Regulation of MUC5B and MUC5AC in primary epithelial cells isolated from the human endocervix. (A) Representative immunofluorescence for E-cadherin, vimentin, and DAPI (upper panels) and CK18, CK14, and DAPI (lower panels) of the primary epithelial cells isolated from the human endocervix. (B, C) Changes in the mRNA expression of MUC5B and MUC5AC by estradiol and progesterone. Primary human endocervical epithelial cells were treated with estradiol (10 nM) and progesterone (100 nM) at physiological concentrations during pregnancy. Data are represented as the mean ± SD from 3 biological replicate experiments. ***P < .001 using ANOVA with Dunnett’s multiple comparisons test. E2, estradiol; CK, cytokeratin; P4, progesterone; Scale bars, 50 μm.

Figure Legend Snippet: Figure 4. Regulation of MUC5B and MUC5AC in primary epithelial cells isolated from the human endocervix. (A) Representative immunofluorescence for E-cadherin, vimentin, and DAPI (upper panels) and CK18, CK14, and DAPI (lower panels) of the primary epithelial cells isolated from the human endocervix. (B, C) Changes in the mRNA expression of MUC5B and MUC5AC by estradiol and progesterone. Primary human endocervical epithelial cells were treated with estradiol (10 nM) and progesterone (100 nM) at physiological concentrations during pregnancy. Data are represented as the mean ± SD from 3 biological replicate experiments. ***P < .001 using ANOVA with Dunnett’s multiple comparisons test. E2, estradiol; CK, cytokeratin; P4, progesterone; Scale bars, 50 μm.

Techniques Used: Isolation, Immunofluorescence, Expressing

Figure 6. Localization of Escherichia coli, neutrophils, and mucins in the cervical canal of a pregnant mouse model of ascending infection. (A) A schematic illustration of the experimental design. (B and C) Hematoxylin and eosin (H&E) and immunofluorescence staining for MUC5B, MUC5AC, E. coli, and Ly6G on an axial section of murine cervix. Representative images of mice treated with PBS (B) (P1 mouse) or E. coli (C) (E1 mouse). Scale bars, 200 μm. (D, E) H&E and immunofluorescence staining for E. coli and Ly6G on an axial section of the cervix in other mice. Treatment with PBS (D) (P2, P3, P4 mice) or E. coli (E) (E2, E3, E4 mice). The arrowhead represents E. coli antigens. Scale bars, 200 μm. (F) Enlarged views indicated by arrowheads in (E) (E2, E3 mice). Scale bars, 10 μm. (G) The number of Ly6G-positive cells in the cervical mucins per field. Data are represented as the median ± interquartile range. *P < .05. Two-tailed Mann–Whitney U tests. (H-K) mRNA expression of Tnf, Il1b, Muc5b, and Muc5ac in murine cervices after E. coli treatment. Data are represented as the mean ± SD. *P < .05, **P < .01 using a 2-tailed unpaired t test.

Figure Legend Snippet: Figure 6. Localization of Escherichia coli, neutrophils, and mucins in the cervical canal of a pregnant mouse model of ascending infection. (A) A schematic illustration of the experimental design. (B and C) Hematoxylin and eosin (H&E) and immunofluorescence staining for MUC5B, MUC5AC, E. coli, and Ly6G on an axial section of murine cervix. Representative images of mice treated with PBS (B) (P1 mouse) or E. coli (C) (E1 mouse). Scale bars, 200 μm. (D, E) H&E and immunofluorescence staining for E. coli and Ly6G on an axial section of the cervix in other mice. Treatment with PBS (D) (P2, P3, P4 mice) or E. coli (E) (E2, E3, E4 mice). The arrowhead represents E. coli antigens. Scale bars, 200 μm. (F) Enlarged views indicated by arrowheads in (E) (E2, E3 mice). Scale bars, 10 μm. (G) The number of Ly6G-positive cells in the cervical mucins per field. Data are represented as the median ± interquartile range. *P < .05. Two-tailed Mann–Whitney U tests. (H-K) mRNA expression of Tnf, Il1b, Muc5b, and Muc5ac in murine cervices after E. coli treatment. Data are represented as the mean ± SD. *P < .05, **P < .01 using a 2-tailed unpaired t test.

Techniques Used: Infection, Immunofluorescence, Staining, Two Tailed Test, MANN-WHITNEY, Expressing

Image Search Results

Journal: The Journal of clinical endocrinology and metabolism

Article Title: Cervical MUC5B and MUC5AC are Barriers to Ascending Pathogens During Pregnancy.

doi: 10.1210/clinem/dgac545

Figure Lengend Snippet: Figure 3. Localization and quantification of MUC5B and MUC5AC in the human uterus during pregnancy and after trachelectomy. (A) Schema of uterine section. (B-G) Representative MUC5B and MUC5AC expression in the human uterus. Right panels are magnified images. A nonpregnant woman (B and E), a pregnant woman at 35 weeks of gestation (C and F), and a nonpregnant woman after trachelectomy (D and G). (H) The areas of cervical glands in 6 normal pregnant women compared with those in 9 nonpregnant women. (I and J) Quantification of MUC5B- and MUC5AC-positive areas in 6 normal pregnant women and 4 nonpregnant women after trachelectomy compared with those in 9 nonpregnant women. Data are represented as the median ± interquartile range. **P < .01, ***P < .001 using a 2-tailed Mann–Whitney U test. Cx, cervix; Ub, uterine body; Va, vagina; Scale bars, 1 mm.

Article Snippet: These sections were incubated with rabbit polyclonal antibody against MUC5B (Novus Biologicals, #NBP1-92151, RRID:AB 467559, 1:500) or mouse monoclonal antibody against MUC5AC (Novus Biologicals, #NBP2-15196, RRID:AB 2894883, 1:100) overnight at 4 °C, followed by incubation with biotinylated goat antirabbit or rabbit antimouse secondary antibody (#424032 or #424022, Nichirei) at room temperature for 30 minutes.

Techniques: Expressing, MANN-WHITNEY

Journal: The Journal of clinical endocrinology and metabolism

Article Title: Cervical MUC5B and MUC5AC are Barriers to Ascending Pathogens During Pregnancy.

doi: 10.1210/clinem/dgac545

Figure Lengend Snippet: Figure 4. Regulation of MUC5B and MUC5AC in primary epithelial cells isolated from the human endocervix. (A) Representative immunofluorescence for E-cadherin, vimentin, and DAPI (upper panels) and CK18, CK14, and DAPI (lower panels) of the primary epithelial cells isolated from the human endocervix. (B, C) Changes in the mRNA expression of MUC5B and MUC5AC by estradiol and progesterone. Primary human endocervical epithelial cells were treated with estradiol (10 nM) and progesterone (100 nM) at physiological concentrations during pregnancy. Data are represented as the mean ± SD from 3 biological replicate experiments. ***P < .001 using ANOVA with Dunnett’s multiple comparisons test. E2, estradiol; CK, cytokeratin; P4, progesterone; Scale bars, 50 μm.

Techniques: Isolation, Immunofluorescence, Expressing

Journal: The Journal of clinical endocrinology and metabolism

Article Title: Cervical MUC5B and MUC5AC are Barriers to Ascending Pathogens During Pregnancy.

doi: 10.1210/clinem/dgac545

Figure Lengend Snippet: Figure 6. Localization of Escherichia coli, neutrophils, and mucins in the cervical canal of a pregnant mouse model of ascending infection. (A) A schematic illustration of the experimental design. (B and C) Hematoxylin and eosin (H&E) and immunofluorescence staining for MUC5B, MUC5AC, E. coli, and Ly6G on an axial section of murine cervix. Representative images of mice treated with PBS (B) (P1 mouse) or E. coli (C) (E1 mouse). Scale bars, 200 μm. (D, E) H&E and immunofluorescence staining for E. coli and Ly6G on an axial section of the cervix in other mice. Treatment with PBS (D) (P2, P3, P4 mice) or E. coli (E) (E2, E3, E4 mice). The arrowhead represents E. coli antigens. Scale bars, 200 μm. (F) Enlarged views indicated by arrowheads in (E) (E2, E3 mice). Scale bars, 10 μm. (G) The number of Ly6G-positive cells in the cervical mucins per field. Data are represented as the median ± interquartile range. *P < .05. Two-tailed Mann–Whitney U tests. (H-K) mRNA expression of Tnf, Il1b, Muc5b, and Muc5ac in murine cervices after E. coli treatment. Data are represented as the mean ± SD. *P < .05, **P < .01 using a 2-tailed unpaired t test.

Techniques: Infection, Immunofluorescence, Staining, Two Tailed Test, MANN-WHITNEY, Expressing

Review

Structured Review

Images

1) Product Images from "Cervical MUC5B and MUC5AC are Barriers to Ascending Pathogens During Pregnancy."

Similar Products

Image Search Results